References
- Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.
- Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of PCOS. Hum Reprod. 2018;33(9):1602–18.
- Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the pathophysiology of PCOS. Endocr Rev. 2015;36(5):487–525.
- Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in PCOS: AE-PCOS Society position statement. Fertil Steril. 2009;92(6):1966–82.
- Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–29.
- Mulders AG, Laven JS, Eijkemans MJ, Hughes EG, Fauser BC. Patient predictors for outcome of gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility: a meta-analysis. Hum Reprod Update. 2003;9(5):429–49.
- Dokras A. Mood and anxiety disorders in women with PCOS. Semin Reprod Med. 2008;26(2):182–95.
- Johnson NP. Metformin use in women with PCOS. Aust N Z J Obstet Gynaecol. 2014;54(5):487–91.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. Fertil Steril. 2004;81(1):19–25.
- Carmina E, Lobo RA. Polycystic ovary syndrome: arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84(6):1897–9.
- Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853–61.
- Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
- Homburg R. Polycystic ovary syndrome. Reprod Biomed Online. 2002;4(3):232–41.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
- Aromataris E, Munn Z, eds. JBI Manual for Evidence Synthesis. Joanna Briggs Institute; 2020.
- Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.
- Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.
- Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions. BMJ. 2017;358:j4008.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.
- Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of PCOS: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–55.
- Carmina E, Campagna AM, Lobo RA. A 20-year follow-up of young women with PCOS: reproductive and metabolic outcomes. Hum Reprod. 2012;27(5):1203–10.
- International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Updated 2024. Available from: https://www.icmje.org
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.
- Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions. BMJ. 2017;358:j4008.
- Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the pathophysiology of PCOS. Endocr Rev. 2015;36(5):487–525.
- Mulders AG, Laven JS, Eijkemans MJ, Hughes EG, Fauser BC. Patient predictors for outcome of gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility: a meta-analysis. Hum Reprod Update. 2003;9(5):429–49.
- Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.
- Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–29.
- González F. Inflammation in PCOS: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77(4):300–5.
- Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in PCOS. Endocr Rev. 2009;30(1):1–50.
- Fauser BC, Devroey P, Diedrich K, Balaban B, Bonduelle M, Delemarrevan de Waal HA, et al. Health outcomes of children born after IVF/ICSI. Hum Reprod Update. 2014;20(3):232–48.
- Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, et al. Definition and significance of polycystic ovarian morphology. Hum Reprod Update. 2014;20(3):334–52.
- Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Müllerian hormone as a surrogate for antral follicle count. J Clin Endocrinol Metab. 2006;91(3):941–5.
- Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Müllerian hormone in women. Hum Reprod Update. 2014;20(3):370–85.
- Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of PCOS. Hum Reprod. 2018;33(9):1602–18.
- Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in PCOS. N Engl J Med. 1998;338(26):1876–80.
- Spritzer PM. Management of metabolic disturbances in PCOS. Arch Endocrinol Metab. 2019;63(3):310–8.
- Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Nijher GM, Comninos AN, et al. Ovarian hyperstimulation syndrome prevention strategies: a review. Hum Reprod Update. 2020;26(5):737–65.
- Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–84.
- Witchel SF, Oberfield SE, Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocr Soc. 2019;3(8):1545–73.